41892-81-3

Usage

Uses

Used in Flavor and Fragrance Industry:
ETHYL 2-ACETYL-4-OXOPENTANOATE is used as a flavoring agent for its fruity odor, contributing to the creation of artificial flavorings and perfumes.
Used in Pharmaceutical Industry:
ETHYL 2-ACETYL-4-OXOPENTANOATE is used as an intermediate in the production of various pharmaceuticals, playing a crucial role in the synthesis of essential medicinal compounds.
Used in Chemical Synthesis:
ETHYL 2-ACETYL-4-OXOPENTANOATE is used as a key intermediate for the synthesis of pyrazoles, pyrazolines, and cyclopentenones, which are important in the development of different chemical products.
Used as a Solvent:
ETHYL 2-ACETYL-4-OXOPENTANOATE is used as a solvent for nitrocellulose, cellulose acetate, and other cellulose ethers, facilitating the processing and application of these materials in various industries.
Used in Dye Production:
ETHYL 2-ACETYL-4-OXOPENTANOATE is used in the production of dyes, where its chemical properties contribute to the creation of a diverse range of colorants for various applications.
Used in Organic Compounds:
ETHYL 2-ACETYL-4-OXOPENTANOATE is used as a solvent for organic compounds, enabling the dissolution and manipulation of various organic substances in chemical processes.

InChI:InChI=1/C9H14O4/c1-4-13-9(12)8(7(3)11)5-6(2)10/h8H,4-5H2,1-3H3

Upstream product

• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 78-95-5 chloroacetone 
• 674-82-8 4-methyleneoxetan-2-one 
• 2009-97-4 ethyl 2-diazo-3-oxobutanoate 
• 141-97-9 ethyl acetoacetate 
• 598-31-2 1-bromoacetone 
• 610-89-9 2-acetyl-pent-4-enoic acid ethyl ester 
• 122132-51-8 3-ethoxycarbonyl-5-iodomethyl-2-methyl-4,5-dihydrofuran 
• 105104-40-3 Okahara's reagent 
• 122132-58-5 ethyl 2-methyl-5-methylene-4,5-dihydrofuran-3-carboxylate 

Downstream Products

• 113186-19-9 1-(4-hydroxy-5-isopropyl-2-methyl-phenyl)-2,5-dimethyl-pyrrole-3-carboxylic acid ethyl ester 
• 636-44-2 2,5-dimethylfuran-3-carboxylic acid 
• 29113-63-1 ethyl 2,5-dimethyl-3-furoate 
• 2758-18-1 3-Methyl-2-cyclopenten-1-one 
• 110-13-4 2,5-hexanedione 
• 500728-34-7 2,5-dimethyl-1-(2-methylphenyl)-1H-pyrrole-3-carboxylic acid 
• 76546-68-4 2,5-dimethyl-1-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester 
• 647843-34-3 1-(4-ethoxy-phenyl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Application RNA-helicase DHX33 inhibitor in preparation of medicine for treating leukemia

The invention discloses application of RNA-helicase DHX33 inhibitor in preparation of a medicament for treating or assisting in treating leukemia. The invention establishes an important role DHX33 protein in developing the leukemia, and the provided small molecule compound has the effect of inhibiting DHX33 helicase activity, thereby promoting DHX33 family protein mediated leukemia cancer apoptosis regulated by BCL - 2.

N-sulfonyl heterocyclic derivative and pharmaceutical application thereof

The invention discloses an N-sulfonyl heterocyclic derivative and pharmaceutical application thereof. The structure of the N-sulfonyl heterocyclic derivative is shown as a formula I in the specification. Experiments show that the compound provided by the invention can effectively inhibit hepatitis B virus core protein assembly and hepatitis B virus replication. The compound provided by the invention has wide application prospects in preparation of hepatitis B virus core protein assembly inhibitors, anti-hepatitis B virus medicines and medicines for preventing and/or treating hepatitis B virus infection related diseases (such as hepatitis B, liver cirrhosis and liver cancer).

Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity

The Wnt family of proteins are secreted signaling proteins that play key roles in regulating cellular functions. Recently, carboxylesterase Notum was shown to act as a negative regulator of Wnt signaling by mediating the removal of an essential palmitoleate. Here we disclose two new chemical scaffolds that inhibit Notum enzymatic activity. Our approach was to create a fragment library of 250 acids for screening against Notum in a biochemical assay followed by structure determination by X-ray crystallography. Twenty fragments were identified as hits for Notum inhibition, and 14 of these fragments were shown to bind in the palmitoleate pocket of Notum. Optimization of 1-phenylpyrrole 20, guided by structure-based drug design, identified 20z as the most potent compound from this series. Similarly, the optimization of 1-phenylpyrrolidine 8 gave acid 26. This work demonstrates that inhibition of Notum activity can be achieved by small, drug-like molecules possessing favorable in vitro ADME profiles.

Urea decomposition: Efficient synthesis of pyrroles using the deep eutectic solvent choline chloride/urea

A simple and efficient method is reported for the synthesis of pyrroles via condensation of a series of tricarbonyl compounds with ammonia, which was generated in situ from decomposition of the deep eutectic solvent choline chloride/urea.

Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against Mycobacterium tuberculosis

In an effort to discover novel inhibitors of M. tuberculosis Caseinolytic proteases (ClpP1P2), a combination strategy of virtual high-throughput screening and in vitro assay was employed and a new pyrrole compound, 1-(2-chloro-6-fluorobenzyl)-2, 5-dimethyl-4-((phenethylamino)methyl)-1H-pyrrole-3-carboxylate was found to display inhibitory effects against H37Ra with an MIC value of 77 μM. In order for discovery of more potent anti-tubercular agents that inhibit ClpP1P2 peptidase in M. tuberculosis, a series of pyrrole derivatives were designed and synthesized based on this hit compound. The synthesized compounds were evaluated for in vitro studies against ClpP1P2 peptidase and anti-tubercular activities were also evaluated. The most promising compounds 2-(4-bromophenyl)-N-((1-(2-chloro-6-fluorophenyl)-2, 5-dimethyl-1H- pyrrolyl)methyl)ethan-1-aminehydrochloride 7d, ethyl 4-(((4-bromophenethyl) amino) methyl)-2,5-dimethyl-1-phenyl-1H-pyrrole-3-carboxylate hydrochloride 13i, ethyl 1-(4-chlorophenyl)-4-(((2-fluorophenethyl)amino)methyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxylate hydrochloride 13n exhibited favorable anti-mycobacterial activity with MIC value at 5 μM against Mtb H37Ra, respectively.

Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site

The K-Ras GTPase is a major target in anticancer drug discovery. However, direct interference with signaling by K-Ras has not led to clinically useful drugs yet. Correct localization and signaling by farnesylated K-Ras is regulated by the prenyl binding protein PDEδ. Interfering with binding of PDEδ to K-Ras by means of small molecules provides a novel opportunity to suppress oncogenic signaling. Here we describe the identification and structure-guided development of novel K-Ras–PDEδ inhibitor chemotypes based on pyrrolopyridazinones and pyrazolopyridazinones that bind to the farnesyl binding pocket of PDEδ with low nanomolar affinity. We delineate the structure–property relationship and in vivo pharmacokinetic (PK) and toxicokinetic (Tox) studies for pyrazolopyridazinone-based K-Ras–PDEδ inhibitors. These findings may inspire novel drug discovery efforts aimed at the development of drugs targeting oncogenic Ras.

Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality

CB2-based therapeutics show strong potential in the treatment of diverse diseases such as inflammation, multiple sclerosis, pain, immune-related disorders, osteoporosis and cancer, without eliciting the typical neurobehavioral side effects of CB1 ligands. For this reason, research activities are currently directed towards the development of CB2 selective ligands. Herein, the synthesis of novel heterocyclic-based CB2 selective compounds is reported. A set of 2,5-dialkyl-1-phenyl-1H-pyrrole-3-carboxamides, 5-subtituted-2-(acylamino)/(2-sulphonylamino)-thiophene-3-carboxylates and 2-(acylamino)/(2-sulphonylamino)-tetrahydrobenzo[b]thiophene-3-carboxylates were synthesized. Biological results revealed compounds with remarkably high CB2 binding affinity and CB2/CB1 subtype selectivity. Compound 19a and 19b from the pyrrole series exhibited the highest CB2 receptor affinity (Ki= 7.59 and 6.15 nM, respectively), as well as the highest CB2/CB1 subtype selectivity (～70 and ～200-fold, respectively). In addition, compound 6b from the tetrahydrobenzo[b]thiophene series presented the most potent and selective CB2 ligand in this series (Ki= 2.15 nM and CB2 subtype selectivity of almost 500-fold over CB1). Compound 6b showed a full agonism, while compounds 19a and 19b acted as inverse agonists when tested in an adenylate cyclase assay. The present findings thus pave the way to the design and optimization of heterocyclic-based scaffolds with lipophilic carboxamide and/or retroamide substituent that can be exploited as potential CB2 receptor activity modulators.

Understanding the Scope of Feist–Bénary Furan Synthesis: Chemoselectivity and Diastereoselectivity of the Reaction Between α-Halo Ketones and β-Dicarbonyl Compounds

Feist–Bénary furan synthesis, the reaction between α-halocarbonyl and β-dicarbonyl compounds, has been known as an efficient method for generating many different types of furans containing a carbonyl group at C-3. However, it has also been reported that, under similar reaction conditions, intermediate tricarbonyl species could be further converted to alternative furan isomers through the application of a Paal–Knorr synthesis. In this manuscript, we investigate the chemoselectivity and diastereoselectivity of furan synthesis from α-halo ketones and β-dicarbonyl compounds, by carrying out the separation and characterization of the intermediates involved in the reaction. Additionally, a one-pot Feist–Bénary furan synthesis from α-halo ketones and β-dicarbonyl compounds without any base or solvent has also been developed.

Design, synthesis and antifungal activity of novel furancarboxamide derivatives

Twenty-seven novel furancarboxamide derivatives with a diphenyl ether moiety were synthesized and evaluated for their antifungal activity against Rhizoctonia solani, Botrytis cirerea, Valsa Mali and Sphaceloma ampelimum. Antifungal bioassay results indicated that most compounds had good or excellent fungicidal activities for R. solani and S. ampelimum at 20 mg L-1. Among synthesized compounds, compound 18e showed a greater inhibitory effect against S. ampelimum, with half maximal effective concentration (EC50) values of 0.020 mg L-1. This strong activity rivals currently used commercial fungicides, such as Boscalid and Carbendazim, and has great potential as a lead compound for future development of novel fungicides.

Quinoline derivatives and their use

The invention discloses a quinoline derivative and a usage thereof, a compound with a structure as shown in a formula (I) and or a pharmaceutically acceptable salt of the compound. The compound or the pharmaceutically acceptable salt thereof disclosed by the invention can be applied to the field of preparation of drugs for preventing or treating tumors.